Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer
Glycolysis is elevated in many cancers. In this study, the authors show that lactoylglutathione, a by-product of methylglyoxal produced from increased glycolysis, is elevated in lung cancer in mouse models and humans, arguing reactive metabolite production can be a liability for cancers.
Enregistré dans:
Auteurs principaux: | Alba Luengo, Keene L. Abbott, Shawn M. Davidson, Aaron M. Hosios, Brandon Faubert, Sze Ham Chan, Elizaveta Freinkman, Lauren G. Zacharias, Thomas P. Mathews, Clary B. Clish, Ralph J. DeBerardinis, Caroline A. Lewis, Matthew G. Vander Heiden |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2019
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/ffedc81cd29a41c396c00462dba0a351 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Detection of glucose-derived d- and l-lactate in cancer cells by the use of a chiral NMR shift reagent
par: Eul Hyun Suh, et autres
Publié: (2021) - Products Liability
-
Risk management of contingent liabilities within a sovereign asset-liability framework
par: Currie, Elizabeth, et autres
Publié: (2014) -
Glycolytic regulation of cell rearrangement in angiogenesis
par: Bert Cruys, et autres
Publié: (2016) -
Journal of products and toxics liability
Publié: (1993)